<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001828</url>
  </required_header>
  <id_info>
    <org_study_id>POLARIS2020-002</org_study_id>
    <nct_id>NCT05001828</nct_id>
  </id_info>
  <brief_title>Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia</brief_title>
  <official_title>Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polaris Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polaris Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine&#xD;
      for treatment of subjects with previously treated or untreated with high risk factor acute&#xD;
      myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients,&#xD;
      and ADI-PEG 20 will be added to this regimen in a phase IA/B study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single arm, phase 1 trial with recommended phase 2 dose (RP2D) cohorts&#xD;
      based on subject inclusion criteria.&#xD;
&#xD;
      Lead In: 6 patients will be enrolled to be treated with standard dose of azacitidine and&#xD;
      venetoclax and the expected RP2D of ADI-PEG 20 (dose level 0). In case of DLT occurring in &gt;1&#xD;
      patient in cycle 1, 6 additional patients will be accrued at dose level -1 of ADI-PEG 20&#xD;
      while keeping the doses of azacitidine and venetoclax unchanged (Dose level -1). Enrollment&#xD;
      to cohort 1 and 2 will start after ≤1 patient out of 6 encounters DLT in cycle 1 at one of&#xD;
      these dose levels. The 6 patients enrolled at that dose level will be counted for efficacy&#xD;
      analysis in Cohort 1. Cohort 1: Relapsed or refractory AML: target response 25%. Historical&#xD;
      expectation for venetoclax and azacitidine is 15%.&#xD;
&#xD;
      Cohort 2: Newly diagnosed high risk AML: Target response 55%. Historical expectation for&#xD;
      venetoclax and azacitidine is 40%.&#xD;
&#xD;
      Treatment may be continued for a total of 24 cycles, each of 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the RP2D of ADI-PEG 20 in combination with venetoclax and azacitidine, per the number of subjects with treatment-related adverse events by current CTCAE</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine preliminary evidence of tumor activity, per the revised 2017 European LeukemiaNet criteria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the peripheral blood arginine levels of ADI-PEG 20 in combination with venetoclax and azacitidine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the peripheral blood citrulline levels of ADI-PEG 20 in combination with venetoclax and azacitidine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the anti-drug antibodies of ADI-PEG 20 in combination with venetoclax and azacitidine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myeloid Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>Previously Treated AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously treated AML based on the revised 2017 European LeukemiaNet (ELN) criteria with age at least 18 years, and having ≥10% blasts in bone marrow or peripheral blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated AML With High Risk Features</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untreated AML per ELN criteria with high risk features, or age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75 years, cardiac disease or prior anthracycline use or high probability of treatment-related mortality</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADI-PEG 20</intervention_name>
    <description>ADI-PEG 20 in combination with venetoclax and azacitidine</description>
    <arm_group_label>Previously Treated AML</arm_group_label>
    <arm_group_label>Untreated AML With High Risk Features</arm_group_label>
    <other_name>Venetoclax</other_name>
    <other_name>Azacitidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lead In and Cohort 1&#xD;
&#xD;
               1. Previously treated AML based on the revised 2017 European LeukemiaNet (ELN)&#xD;
                  criteria and having ≥10% blasts in bone marrow or peripheral blood&#xD;
&#xD;
               2. Age ≥18 years&#xD;
&#xD;
          -  Cohort 2&#xD;
&#xD;
               1. Untreated AML per ELN criteria with high risk features&#xD;
&#xD;
               2. Age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75&#xD;
                  years, cardiac disease or prior anthracycline use or high probability of&#xD;
                  treatment-related mortality&#xD;
&#xD;
          -  Life expectancy reasonably adequate for evaluating the treatment&#xD;
&#xD;
          -  White blood cell (WBC) count of 10 × 109/L or less. (Use of hydroxyurea to control WBC&#xD;
             is allowed till 48 hours prior to protocol treatment)&#xD;
&#xD;
          -  Adequate renal function: Creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine&#xD;
             clearance &gt; 40 mL/minute (measured or calculated according to the Cockcroft-Gault&#xD;
             formula)&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  ALT and AST both ≤ 2.5 x institutional ULN or ≤ 5 times the ULN for patients with&#xD;
                  leukemic involvement of liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for antecedent hematological disorders with hypomethylating agent&#xD;
             (more than 2 cycles, those with exposure to &lt;2 cycles will be allowed), venetoclax, or&#xD;
             chemotherapy for antecedent hematologic disorders (treatment with other agents&#xD;
             including hydroxyurea for myelodysplastic syndrome or myeloproliferative neoplasm is&#xD;
             permitted)&#xD;
&#xD;
          -  Favorable risk AML per ELN 2017 criteria&#xD;
&#xD;
          -  Known active CNS involvement by leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

